Kansere ya prostate ke monanaka mingi nki mutindu?
Kansere ya prostate kele mosi na kati ya kansere yina ke belaka mingi babakala, mingi-mingi bayina me kuma bambuta.
Na kutadila kimvuka mosi (American Cancer Society), kansere ya prostate kele kansere ya zole ya kuluta mingi na Amerika, na nima ya kansere ya mpusu ya nitu.
Na États-Unis, na babakala 9, bakala mosi ke belaka kansere ya prostate na luzingu na yandi.
Na mvu 2021, bo ke yindula nde bantu 248 530 ta bela kansere ya prostate mpi bantu 34 130 ta fwa na kansere ya prostate.
Kansi, yo kele mfunu na kuzaba nde kana bo me zaba kansere ya prostate na luyantiku, yo kele mpasi ve na kubelula yo mpi bantu mingi ke gulukaka.
Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R: Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 808-15.
Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y: [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012, 33 (10): 1056-9.
Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006, 13 (3): 158-68.
Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E: Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012, 36 (2): 122-7.
Yu XQ, Luo Q, Smith DP, Clements MS, O'Connell DL: Prostate cancer prevalence in New South Wales Australia: a population-based study. Cancer Epidemiol. 2015, 39 (1): 29-36.
Ondrusova M, Mrozova L, Ondrus D, Mrinakova B: Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012. Neoplasma. 2013, 60 (4): 446-51.
['Disclaimer: mambu ya kimunganga']
['Site Internet yai kele kaka sambu na kulonga mpi kupesa bansangu, kansi yo kele ve sambu na kupesa bandongisila ya minganga to kusadila bantu ya nkaka kisalu.']
['Bo fwete sadila ve bansangu yina bo kepesa sambu na kuzaba to kubelula maladi mosi buna, mpi bantu yina kesosa bandongisila ya kimunganga fwete solula ti munganga yina kele ti nswa ya kusala kisalu yina.']
['Tala nde, ba-apareyi yina ke pesaka bamvutu na bangiufula ke vandaka ve mbote ntangu bo ke sadilaka ntalu, mu mbandu ntalu ya bantu yina bo me zaba nde bo ke belaka maladi mosi buna.']
['Sosa ntangu yonso bandongisila ya munganga to ya muntu ya nkaka ya me zaba kisalu ya kusansa bantu sambu na maladi na nge. Kuvila ve bandongisila ya munganga to kusukinina ve na kusosa yo sambu na mambu ya nge me tanga na site Internet yai. Kana nge ke yindula nde nge kele ti maladi ya ngolo, binga 911 to kwenda nswalu na lupitalu ya me finama. Site Internet yai to mutindu nge ke sadila yo ke sala ve nde nge kuma nduku ya munganga to nkengi ya maladi.']
['Banswa ya kusonika']
['Nsiku ya Banswa ya Bansoniki ya Internet ya mvu 1998, 17 U.S.C. § 512 (DMCA) ke pesa nswa na bantu yina kele ti banswa ya bansoniki ya ke kwikila nde mambu yina ke monana na Internet ke fwa banswa na bo na nsi ya nsiku ya banswa ya bansoniki ya États-Unis. ']
['Kana nge ke mona nde mambu ya nge ke tanga na site Internet na beto to na baservice na beto ke fwa banswa na nge, nge (to muntu yina ke twadisaka nge) lenda tindila beto mukanda sambu na kulomba nde beto katula yo to kukanga nzila na nge ya kusadila yo.']
['Bo fwete tinda bansangu na mukanda na nzila ya email (tala na "Kutuba na beto" sambu na kuzaba adresi ya email).']
['Nsiku ya DMCA ke lomba nde na mukanda na nge ya ke tubila nde bo me fwa nsiku ya banswa ya bantu, nge sonika mambu yai: (1) mutindu ya kutendula kisalu yina bo me fwa nsiku; (2) mutindu ya kutendula mambu yina bo me fwa nsiku mpi bansangu yina ta sadisa beto na kuzaba kisika yina mambu yango kele; (3) bansangu ya nge lenda sadila sambu na kusolula ti nge, tanga mpi adresi na nge, nimero ya telefone mpi adresse ya e-mail; (4) mambu ya nge me tuba nde nge ke kwikila nde mambu yina nge ke tuba kele ve na nswa ya munkwa-kisalu to muntu yina me pesa nswa na yo to na nsiku ya leta.']
['5) na nima ya kupesa nzikisa na mukanda yina nge me sonika, nge fwete ndima nde mambu yina nge me tuba kele ya kieleka mpi nde nge kele ti nswa ya kusadila banswa yina bo me bebisa.']
['mpi (6) kidimbu ya muntu yina kele ti nswa ya kubasisa yo to ya muntu yina kele ti nswa ya kusala mambu na zina na yandi. ']
['Kana nge pesa ve bansangu yai yonso, yo lenda sala nde bo sala ve mambu nswalu.']
['Kusolula']
['Beno tindila beto email kana beno kele na ngyufula to ngindu.']
How common is prostate cancer?
Prostate cancer is one of the most common types of cancer in men, particularly in older men.
According to the American Cancer Society, prostate cancer is the second most common cancer in American men, behind skin cancer.
In the United States, about 1 in 9 men will be diagnosed with prostate cancer during their lifetime.
In 2021, it is estimated that there will be about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.
However, it is important to note that prostate cancer is highly treatable, and the survival rate is high when it is detected early.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na kiteso ya']
['BioMedLib kesadilaka ba ordinatere ya bo mesalaka bo mosi (ba algorithme ya kulonguka na masini) sambu na kubasisa bangyufula ti bamvutu.']
['Beto me yantika ti mikanda ya kimunganga ya bamilio 35 ya PubMed/Medline mpi basite ya Internet ya RefinedWeb.']
